Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia
Status:
Terminated
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safest dose of the BCR-ABL inhibitor XL228, how
often it should be taken, and how well people with leukemia tolerate XL228.